Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMYMP) EBITDA (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed EBITDA for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly EBITDA rose 255.96% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 billion through Dec 2025, up 178.34% year-over-year, with the annual reading at $6.8 billion for FY2025, 178.32% up from the prior year.
  • EBITDA for Q4 2025 was $1.1 billion at Bristol Myers Squibb, down from $2.2 billion in the prior quarter.
  • The five-year high for EBITDA was $2.5 billion in Q4 2021, with the low at -$11.8 billion in Q1 2024.
  • Average EBITDA over 5 years is $988.4 million, with a median of $1.6 billion recorded in 2021.
  • The sharpest move saw EBITDA soared 769.39% in 2021, then crashed 640.92% in 2024.
  • Over 5 years, EBITDA stood at $2.5 billion in 2021, then tumbled by 37.42% to $1.6 billion in 2022, then fell by 5.06% to $1.5 billion in 2023, then crashed by 79.89% to $302.0 million in 2024, then skyrocketed by 255.96% to $1.1 billion in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $1.1 billion, $2.2 billion, and $1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.